Aveanna Healthcare Holdings

AVAH · NASDAQ

$12.75+$0.31 (+2.49%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $12.44

AVAH analyst rating

BuyConsensus of 10 analysts over the last 12 months. 70% rate it a buy.

Strong buy1
Buy6
Hold3
Underperform0
Sell0

12-month price target · 12 analysts

Average $14.85 (+16.4% upside)

Low: $13.13
Now: $12.75
High: $16.80

Upgrades and downgrades

The latest rating actions, newest first

AVAH analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Sep 14, 2026	Maintains	Neutral	$8.00 → $15.00	71%
Barclays	Aug 28, 2026	Maintains	Overweight	$9.50 → $15.00	59%
Truist Securities	Aug 24, 2026	Maintains	Hold	$11.00 → $15.00	67%
RBC Capital	Aug 24, 2026	Maintains	Outperform	$10.00 → $16.00	57%
UBS	Aug 14, 2026	Maintains	Neutral	$8.00 → $13.00	64%
Raymond James	Aug 14, 2026	Maintains	Strong Buy	$13.00 → $15.00	65%
BMO Capital	Aug 14, 2026	Maintains	Outperform	$10.00 → $14.00	41%
Truist Securities	Jul 14, 2026	Maintains	Hold	$9.00 → $11.00	67%
Barclays	Jul 9, 2026	Maintains	Overweight	$9.00 → $9.50	59%
RBC Capital	Jun 3, 2026	Upgrade	Sector Perform → Outperform	$10.00	57%

The case for and against

Updated Oct 14, 2026

Bull case

Aveanna Healthcare Hldgs is positioned to benefit from durable demand for home-based care, where its differentiated private-duty nursing platform serves medically complex children in a far lower-cost setting than inpatient care, reinforcing value for Medicaid MCOs and state payors. Preferred payor momentum is strengthening across segments, with PDS preferred payor MCO volume at 64%, home health episodic mix at 81%, and Medical Solutions agreements rising to 20 of 25 targeted, while management now expects double-digit annual revenue growth and raised long-term organic targets. The outlook is further supported by a California Medi-Cal PDN rate increase effective January 2027, improving reimbursement visibility, helping expand capacity, and supporting modeled adjusted EBITDA of $370.7 million in 2026 and $400.6 million in 2027.

Bear case

Aveanna Healthcare Hldgs is viewed negatively because its earnings outlook is highly exposed to labor headwinds, with continued nurse shortages expected to pressure FY27 adjusted EBITDA by 10% in the downside case. Its heavy reliance on government reimbursement, especially Medicaid and Medicaid MCO in Private Duty Services, adds policy and rate-settlement risk, while regulatory, audit, and reimbursement-system changes could further compress margins. The company’s valuation also appears vulnerable if legislative rate initiatives and its preferred payor strategy stall, and high leverage, acquisition integration risk, and limited cross-selling synergy could keep multiple expansion constrained.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.